Journey Medical (DERM) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $61.9 million for 2025, up 10% from $56.1 million in 2024.

Net Product Revenue: $14.7 million from Emrosi since its launch in March 2025.

Gross Margin: Improved to 66.2% from 62.8% in 2024.

SG&A Expenses: Increased to $44.4 million, up 10% from $40.2 million in 2024 due to launch-related activities.

GAAP Net Loss: $11.4 million ($0.47 per share), narrowed from a loss of $14.7 million ($0.72 per share) in 2024.

Adjusted EBITDA: Positive at $2.9 million, compared to $800,000 in 2024.

Cash Position: Ended 2025 with $24.1 million, up from $20.3 million in 2024.

2Strategic Updates and Business Highlights

Product Launch: Emrosi, an oral treatment for rosacea, launched successfully with strong prescription volume (53,000 prescriptions in 2025).

Market Access: Approximately 100 million commercial lives have access to Emrosi, with contracts in place with two of the top three group purchasing organizations (GPOs).

Clinical Validation: Positive Phase III trial results published in JAMA Dermatology; Emrosi's efficacy and safety profile received strong endorsements.

Sales Force Expansion: Plans to increase the sales force in Q3 2026 to support Emrosi's growth.

Future Products: Anticipation of launching 1-2 additional dermatology products in 2026.

3Forward Guidance and Outlook

2026 Expectations: Continued growth in Emrosi sales anticipated, with expectations for positive adjusted EBITDA and improved reimbursement rates as health plans adopt Emrosi.

Prescription Growth: Anticipated annualized prescription run rate for Emrosi expected to exceed 126,000 in 2026.

Market Position: Positioned for significant growth in the dermatology market, with a focus on expanding prescriber base and improving patient experiences.

4Bad News, Challenges, or Points of Concern

Competitive Pressures: Legacy products, particularly the Accutane franchise, faced challenges due to generic competition.

Prescription Trends: Q1 2026 prescriptions showed a flat trend initially, attributed to insurance deductible resets and adverse weather conditions affecting patient visits.

Revenue per Script Variability: Concerns about lower revenue per script in Q4, attributed to reimbursement mix and reliance on co-pay assistance programs.

Timing of Coverage Decisions: The timing of health plan coverage decisions could impact revenue recognition and growth.

5Notable Q&A Insights

Prescription Trends: Management acknowledged Q1 challenges but expressed confidence in surpassing Q4 prescription numbers.

Gross to Net Expectations: Anticipated improvements in gross to net as reimbursement rates improve and coverage expands, with upward pressure expected throughout 2026.

Inventory Management: Inventory levels were reported as being on track, with no significant concerns raised regarding channel inventory.

Future Publications: Plans to publish additional clinical data supporting Emrosi's efficacy and economic value, which could enhance market acceptance. Overall, Journey Medical reported a strong year driven by the successful launch of Emrosi, with a positive outlook for continued growth despite some challenges in the competitive landscape and prescription trends.